16-17 May 2013 - OECD Congress Center, Paris, France
This workshop will review progress in human carcinogenesis safety evaluation strategies and cancer risk assessment.
Co-organized by
- ILSI Health and Environmental Sciences Institute's Application of Genomics to Mechanism-Based Risk Assessment Technical Committee (Genomics)
- Maastricht University, Department of Toxicogenomics
The current safety paradigm for assessing carcinogenic properties of drugs, cosmetics,
industrial chemicals, and environmental exposures relies mainly on in vitro genotoxicity
testing followed by 2-year rodent bioassays. Although this paradigm developed
in 1960s has protected consumers from chemical carcinogens, the low specificity
of in vitro assays and the reliance on expensive 2-year rodent bioassays with many
rodent tumor findings that are of questionable human relevance provides a strong
impetus for the development of novel testing methods that exploit 21st century
science including “omics” technologies, systems toxicology and bioinformatics.
At the preceding Workshop held in Venice in August 2009, a roadmap for the development
and application of toxicogenomic methods has been proposed based
on discussions among opinion leaders from academia, industry and regulatory
agencies in the US and EU (Paules et al 2010, EHP 199(6): 739ff).
industrial chemicals, and environmental exposures relies mainly on in vitro genotoxicity
testing followed by 2-year rodent bioassays. Although this paradigm developed
in 1960s has protected consumers from chemical carcinogens, the low specificity
of in vitro assays and the reliance on expensive 2-year rodent bioassays with many
rodent tumor findings that are of questionable human relevance provides a strong
impetus for the development of novel testing methods that exploit 21st century
science including “omics” technologies, systems toxicology and bioinformatics.
At the preceding Workshop held in Venice in August 2009, a roadmap for the development
and application of toxicogenomic methods has been proposed based
on discussions among opinion leaders from academia, industry and regulatory
agencies in the US and EU (Paules et al 2010, EHP 199(6): 739ff).
This follow-up workshop will be held with the goal to review progress in human
carcinogenesis safety evaluation strategies and cancer risk assessment.
Experts and opinion leaders from academia, industry and regulatory agencies
in the US, EU and Asia, will convene to discuss the utility of exploiting
genomics approaches in understanding genotoxicity findings and in chemical
carcinogenicity risk assessment, as well as the informatics needs to support
optimal access and use of these data. Novel assay development and promising
emerging data mining and modeling approaches will be discussed with particular
emphasis on identifying gaps and opportunities for their application in
human cancer risk assessment.
Programme:
• Session 1: Utility of Toxicogenomics Approaches in Risk Assessment of Genotoxicity Findings
• Session 2: Toxicogenomic Approaches in Chemical Carcinogenicity Risk Assessment
• Session 3: Informatics Challenges
• Session 2: Toxicogenomic Approaches in Chemical Carcinogenicity Risk Assessment
• Session 3: Informatics Challenges
Please contact Dr. Raegan O’Lone, rolone@hesiglobal.org, with questions.
0 comments:
Post a Comment